- Home
- ALX vs PHVS Comparison
ALX vs PHVS Comparison
Compare ALX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALX
- PHVS
- Stock Information
- Founded
- ALX 1928
- PHVS 2015
- Country
- ALX United States
- PHVS Switzerland
- Employees
- ALX N/A
- PHVS N/A
- Industry
- ALX Real Estate Investment Trusts
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ALX Real Estate
- PHVS Health Care
- Exchange
- ALX Nasdaq
- PHVS Nasdaq
- Market Cap
- ALX 1.2B
- PHVS 1.3B
- IPO Year
- ALX N/A
- PHVS 2021
- Fundamental
- Price
- ALX $234.35
- PHVS $23.05
- Analyst Decision
- ALX
- PHVS Buy
- Analyst Count
- ALX 0
- PHVS 6
- Target Price
- ALX N/A
- PHVS $36.67
- AVG Volume (30 Days)
- ALX 42.7K
- PHVS 119.1K
- Earning Date
- ALX 11-03-2025
- PHVS 08-12-2025
- Dividend Yield
- ALX 7.75%
- PHVS N/A
- EPS Growth
- ALX N/A
- PHVS N/A
- EPS
- ALX 7.28
- PHVS N/A
- Revenue
- ALX $218,089,000.00
- PHVS N/A
- Revenue This Year
- ALX N/A
- PHVS N/A
- Revenue Next Year
- ALX N/A
- PHVS N/A
- P/E Ratio
- ALX $31.61
- PHVS N/A
- Revenue Growth
- ALX N/A
- PHVS N/A
- 52 Week Low
- ALX $184.76
- PHVS $11.51
- 52 Week High
- ALX $260.84
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- ALX 55.16
- PHVS 55.97
- Support Level
- ALX $226.28
- PHVS $21.41
- Resistance Level
- ALX $236.57
- PHVS $24.52
- Average True Range (ATR)
- ALX 4.68
- PHVS 1.34
- MACD
- ALX 1.10
- PHVS -0.15
- Stochastic Oscillator
- ALX 87.54
- PHVS 47.24
About ALX Alexander's Inc.
Alexander's Inc is a real estate investment trust engaged in leasing, managing, developing and redeveloping its properties. It has six properties in the greater New York City metropolitan area. All of the revenues come from properties located in New York City which include revenues from leasing of space to tenants at their properties and revenues from parking and tenant services.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.